Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_2
4
80%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

NCT00350272
completedphase_1

Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation

NCT00312039
completedphase_2

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

NCT00380159
completedphase_2

An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment

NCT00675844
completedphase_2

Safety Study of Elvucitabine in HIV-1 Subjects

NCT00405249

Clinical Trials (5)

Showing 5 of 5 trials
NCT00350272Phase 2

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

Completed
NCT00312039Phase 1

Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation

Completed
NCT00380159Phase 2

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

Completed
NCT00675844Phase 2

An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment

Completed
NCT00405249Phase 2

Safety Study of Elvucitabine in HIV-1 Subjects

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5